Evolus (EOLS) Cash from Operations Growth (1y) (2018 - 2026)
Evolus (EOLS) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 85.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.53% |
| Mar 31, 2026 | 36.34% |
| Dec 31, 2025 | 166.78% |
| Sep 30, 2025 | -156.36% |
| Jun 30, 2025 | -283.17% |
| Mar 31, 2025 | -47.26% |
| Dec 31, 2024 | 491.39% |
| Sep 30, 2024 | -519.26% |
| Jun 30, 2024 | 51.39% |
| Mar 31, 2024 | 48.44% |
| Dec 31, 2023 | 109.27% |
| Sep 30, 2023 | 94.58% |
| Jun 30, 2023 | 36.28% |
| Mar 31, 2023 | 46.11% |
| Dec 31, 2022 | 2.99% |
| Sep 30, 2022 | 46.92% |
| Jun 30, 2022 | -229.61% |
| Mar 31, 2022 | -358.30% |
| Dec 31, 2021 | -299.12% |
| Sep 30, 2021 | -134.27% |